person · Reporting owner

McLaughlin Brian F

Disclosed activity across 1 company

Tapewire entity: 145859
SEC CIK: 0001790969

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
LIFECORE BIOMEDICAL, INC. \DE\LNDC · Entity 6447	Chief Financial Officer	October 19, 2020	October 21, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

LIFECORE BIOMEDICAL, INC. \DE\

Report date October 19, 2020 · Filed October 21, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	17,053	Ending reported balance After 2020-10-19 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2020-10-19 · Exercise / conversion · Acquired 5,000 · Balance 19,532 F1: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. Row 2 · 2020-10-19 · Tax withholding · Disposed 2,479 · Balance 17,053 F1: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis.
Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2020-10-19	Direct	0	Reported balance After 2020-10-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-10-19 · Exercise / conversion · Disposed 5,000 · Balance 0 F1: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2: The restricted stock units were granted on October 19, 2017. F3: The restricted stock units vested on October 19, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis.

F2: The restricted stock units were granted on October 19, 2017.

F3: The restricted stock units vested on October 19, 2020.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 19, 2020 Filed Oct 21, 2020 00:25 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	Exercise / conversionRestricted Stock Unit · Derivative	5,000	$0.00	$0.00	Disclosure SEC source: 0001593968-20-002079 · primary_01.xml · derivative · entry 3 McLaughlin Brian F · CIK 0001790969 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2020-10-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · shares: The restricted stock units were granted on October 19, 2017. F3 · derivative.exercise_date: The restricted stock units vested on October 19, 2020. F3 · derivative.expiration_date: The restricted stock units vested on October 19, 2020. Read SEC document
October 19, 2020 Filed Oct 21, 2020 00:25 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	Tax withholdingCommon Stock	2,479	$10.09	$25,013.11	Disclosure SEC source: 0001593968-20-002079 · primary_01.xml · nonDerivative · entry 2 McLaughlin Brian F · CIK 0001790969 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,053 F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. Read SEC document
October 19, 2020 Filed Oct 21, 2020 00:25 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	Exercise / conversionCommon Stock	5,000	$10.09	$50,450.00	Disclosure SEC source: 0001593968-20-002079 · primary_01.xml · nonDerivative · entry 1 McLaughlin Brian F · CIK 0001790969 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. Read SEC document
July 23, 2020 Filed Jul 28, 2020 00:04 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantNon-Qualified Stock Option (Right to Buy) · Derivative	64,173	$0.00 Strike: $9.40	$0.00	Disclosure SEC source: 0001593968-20-001671 · primary_01.xml · derivative · entry 2 McLaughlin Brian F · CIK 0001790969 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,173 Underlying: Common Stock · 64,173 shares Expires 2027-07-23 Read SEC document
July 23, 2020 Filed Jul 28, 2020 00:04 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantIncentive Stock Option (Right to Buy) · Derivative	5,827	$0.00 Strike: $9.40	$0.00	Disclosure SEC source: 0001593968-20-001671 · primary_01.xml · derivative · entry 1 McLaughlin Brian F · CIK 0001790969 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,827 Underlying: Common Stock · 5,827 shares Expires 2027-07-23 Read SEC document
April 01, 2020 Filed Apr 3, 2020 18:17 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantIncentive Stock Option (Right to Buy) · Derivative	5,469	$9.77 Strike: $9.77	$53,432.13	Disclosure SEC source: 0001628280-20-004582 · wf-form4_158593784456621.xml · derivative · entry 2 McLaughlin Brian F · CIK 0001790969 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 5,469 shares Expires 2027-04-01 Read SEC document
April 01, 2020 Filed Apr 3, 2020 18:17 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantNonqualified Stock Option (Right to Buy) · Derivative	29,531	$9.77 Strike: $9.77	$288,517.87	Disclosure SEC source: 0001628280-20-004582 · wf-form4_158593784456621.xml · derivative · entry 1 McLaughlin Brian F · CIK 0001790969 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,531 Underlying: Common Stock · 29,531 shares Expires 2027-04-01 Read SEC document
January 07, 2020 Filed Jan 9, 2020 00:50 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantIncentive Stock Option (Right to Buy) · Derivative	9,073	$10.12 Strike: $10.12	$91,818.76	Disclosure SEC source: 0001628280-20-000197 · wf-form4_157853098497755.xml · derivative · entry 2 McLaughlin Brian F · CIK 0001790969 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 9,073 shares Expires 2027-01-07 Read SEC document
January 07, 2020 Filed Jan 9, 2020 00:50 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantNonqualified Stock Option (Right to Buy) · Derivative	15,927	$10.12 Strike: $10.12	$161,181.24	Disclosure SEC source: 0001628280-20-000197 · wf-form4_157853098497755.xml · derivative · entry 1 McLaughlin Brian F · CIK 0001790969 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,927 Underlying: Common Stock · 15,927 shares Expires 2027-01-07 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.